MBX

MBX Biosciences completed its IPO in September 2024, raising approximately $188 million. As of September 22, 2026, the stock price was $62.01, with a market cap of $2.98 billion, and a 52-week range between $9.67 and $72.64. Key events in the past six months include the announcement on August 27, 2026, of the first patient dosed in its pivotal Phase 3 oPTimize trial of once-weekly Canvuparatide. On September 8, 2026, Jeff Held was appointed as Chief Legal Officer, and on September 9, 2026, the company announced its participation in upcoming investor conferences. MBX held a virtual investor event on June 12, 2026, to present once-weekly Canvuparatide presentations at ENDO 2026. On September 23, 2026, an analyst upgraded MBX Biosciences, Inc. to a 'Buy' rating, citing strong Canvuparatide Phase 2 data, a clear path to Phase 3 success, and the potential to challenge the current standard of care. The analyst also highlighted the early-stage obesity pipeline, the company's cash position of $418 million, and multiple near-term catalysts.